21th Century Cures Act advances in U.S. House
Study finds DMT costs up dramatically since 2002
Researchers implicate chemical in MS
Two drugs show promise in remyelination
Relapses, disability progression linked to stopping meds
Teleconference Tonight: Ask a Neurologist
Communications, partnership keys to satisfaction in MS patient care
Biogen drug shows remyelination potential
Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.
The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.
Website Design by SimplexWeb
© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved